Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AETHLON MEDICAL INCAEMD · Entity 8580 | Director · Chief Executive Officer | April 03, 2020 | September 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AETHLON MEDICAL INC
Report date April 03, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2030-04-02 | Direct | 202,280 |
Reported balance
After 2020-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-03 · Grant · Acquired 202,280 · Balance 202,280 F1: The option was granted on 4/3/20, but was contingent on stockholder approval of the Issuer's 2020 Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 9/15/20, and therefore for purposes of Section 16, the option was not "acquired" until such stockholder approval was obtained. One-quarter of the shares subject to the option shall vest twelve months from the 4/3/20 grant date, and the remainder shall vest in equal monthly installments thereafter until fully vested on April 2, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on 4/3/20, but was contingent on stockholder approval of the Issuer's 2020 Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 9/15/20, and therefore for purposes of Section 16, the option was not "acquired" until such stockholder approval was obtained. One-quarter of the shares subject to the option shall vest twelve months from the 4/3/20 grant date, and the remainder shall vest in equal monthly installments thereafter until fully vested on April 2, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2020 Filed Sep 17, 2020 17:06 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantEmployee Stock Option (right to buy) · Derivative | 202,280 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001209191-20-050825 · doc4.xml · derivative · entry 1 RODELL TIMOTHY C JR · CIK 0001260316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,280 Underlying: Common Stock · 202,280 shares Expires 2030-04-02 F1 · derivative.exercise_date: The option was granted on 4/3/20, but was contingent on stockholder approval of the Issuer's 2020 Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 9/15/20, and therefore for purposes of Section 16, the option was not "acquired" until such stockholder approval was obtained. One-quarter of the shares subject to the option shall vest twelve months from the 4/3/20 grant date, and the remainder shall vest in equal monthly installments thereafter until fully vested on April 2, 2024. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 18:41 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantEmployee Stock Option (Right to Buy) · Derivative | 552,625 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001209191-18-062404 · doc4.xml · derivative · entry 1 RODELL TIMOTHY C JR · CIK 0001260316 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,625 Underlying: Common Stock · 552,625 shares Expires 2028-12-09 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest and become exercisable on December 10, 2019, and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.